Business Wire | Apr 26, 2021 04:01PM EDT

ImmunoGen Announces Conference Call to Discuss Its First Quarter 2021 Operating Results

Apr. 26, 2021

WALTHAM, Mass.--(BUSINESS WIRE)--Apr. 26, 2021--ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Monday, May 10, 2021 to discuss its first quarter operating results. Management will also provide a brief update on the business.

Conference Call Information

To access the live call by phone, dial (877) 621-5803; the conference ID is 9982696. The call may also be accessed through the Investors and Media section of the Company's website, www.immunogen.com. Following the call, a replay will be available at the same location.

ABOUT IMMUNOGEN

ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW(tm).

Learn more about who we are, what we do, and how we do it at www.immunogen.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210426005775/en/

CONTACT: INVESTOR RELATIONS AND MEDIA ImmunoGen Courtney O'Konek 781-895-0600 courtney.okonek@immunogen.com

CONTACT: OR

CONTACT: FTI Consulting Robert Stanislaro 212-850-5657 robert.stanislaro@fticonsulting.com